AEON Biopharma (AEON) CFO John Bencich files initial insider ownership report
Rhea-AI Filing Summary
AEON Biopharma, Inc. filed an initial insider ownership report for its Chief Financial Officer, John Bencich. This filing is a Form 3, which serves as the starting disclosure of his beneficial ownership in AEON as an officer. The report does not list any specific transactions or share movements.
Positive
- None.
Negative
- None.
Key Terms
Form 3, beneficial ownership, Chief Financial Officer
3 terms
Form 3 regulatory
"This filing is a Form 3, which serves as the starting disclosure"
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
beneficial ownership financial
"serves as the starting disclosure of his beneficial ownership in AEON"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Chief Financial Officer financial
"filed an initial insider ownership report for its Chief Financial Officer, John Bencich"
A Chief Financial Officer (CFO) is the person in charge of a company's money and financial planning. They decide how to spend, save, and invest funds to help the company grow and stay stable. Their role is important because good financial decisions keep the company healthy and successful.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does the AEON Biopharma (AEON) Form 3 filing report for John Bencich?
The Form 3 filing reports that John Bencich serves as Chief Financial Officer of AEON Biopharma. It functions as his initial statement of beneficial ownership as an officer, without detailing any specific stock purchases, sales, or other insider transactions in the company’s securities.
Does the AEON Biopharma (AEON) Form 3 show any insider buying or selling?
No, the Form 3 does not show any insider buying or selling activity. The transaction summary lists zero buys, zero sells, zero derivative exercises, and no gifts or restructurings, indicating this filing is purely an initial ownership disclosure without trade activity.
Who is the insider named in AEON Biopharma’s (AEON) latest Form 3 filing?
The insider named is John Bencich, who is identified as the Chief Financial Officer of AEON Biopharma. The filing confirms his officer status and role but does not attach any specific share transactions or derivative holdings within this particular disclosure.
Why is AEON Biopharma (AEON) filing a Form 3 for its Chief Financial Officer?
AEON Biopharma is filing a Form 3 because John Bencich, as Chief Financial Officer, is a reporting person under SEC rules. Form 3 serves as his initial statement of beneficial ownership in the company’s securities after he becomes an officer subject to these reporting requirements.
Does the AEON Biopharma (AEON) Form 3 include any derivative securities information?
No, the filing shows an empty derivative summary and a derivative transaction count of zero. This means the disclosure does not list any options, warrants, or other derivative securities for John Bencich in this initial ownership statement, based on the provided data.